A Human Immunodeficiency Virus Superinfection Diagnosed in a Patient on Intramuscular Long-acting Combination of Cabotegravir and Rilpivirine.

A case of a male with human immunodeficiency virus with plasma genotyping detecting no resistance and a CRF02_AG subtype had a controlled HIV RNA on antiretroviral therapy since 2010. We introduced intramuscular therapy with cabotegravir and rilpivirine. One month later, his HIV RNA was 1500 copies/mL; genotyping found a subtype B with many mutations.

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact [e-mail] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [e-mail].

Déclaration de conflit d'intérêts

Potential conflicts of interest. N. V. received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from VIIV. S. L. N. received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from MSD and GILEAD; payment for expert testimony from GILEAD; support for attending meetings and/or travel from GILEAD and VIIV; and participated on a Data Safety Monitoring Board or Advisory Board for GILEAD. E. T. received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from VIIV. J. L. M. received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from VIIV; support for attending meetings and/or travel from VIIV, MSD, and Gilead. L. M. J. received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from ViiV, Merck, and GILEAD; support for attending meetings and/or travel from Gilead and MSD; and participated on a data safety monitoring board or advisory board for ViiV and Gilead. K. L. received grants or contracts from Gilead, MSD, and ViiV Healthcare; consulting fees from Gilead, ViiV Healthcare, and MSD; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Gilead, ViiV Healthcare, and MSD; and support for attending meetings and/or travel from Gilead, ViiV Healthcare, and MSD. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.